Breakthrough device for glioblastoma

Carthera receives FDA breakthrough device designation for SonoCloud-9 system, allowing for enhanced interaction with FDA and recognising SonoCloud system as innovative and promising approach for treatment of recurrent glioblastoma Carthera, a French company that designs and develops SonoCloud, an ultrasound-based medical device to treat a wide range of brain diseases, announced on June 22 2022 that…

Study: Improvements in TBI Patients with Persistent Brain Fog

A new study has shown that plasticity-based brain training can drive improvements in patients with persistent symptoms of Traumatic Brain Injury (TBI). Gains were observed in standard measures of cognition, standard measures of self-reported symptoms, and the connectivity between brain regions. The intervention used in the study was brain exercises from BrainHQ, made by Posit…

In Vitro diagnostic test for assessment of Alzheimer’s disease

The U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorisation for Fujirebio Diagnostics’ Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic (IVD) test for the assessment of β-Amyloid pathology in patients being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is…

Brain-computer interface helps paralysed patient drive again

Almost ten years ago, Aldana Zuniga was paralysed from the waist down in a car accident. Now, a microchip implanted in his brain has helped him get behind the wheel of a car again. Using only his thoughts to control the speed, Zuniga drove laps in a NASCAR Cup racecar on a track in the…

Management of urinary incontinence in adults with MS or SCI

Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to Multiple Sclerosis or Spinal Cord Injury Submission based on data from the pivotal international Phase III CONTENT clinical programme, also recently published in European Urology1 CONTENT showed that Dysport® decreased incontinence episodes, detrusor pressure and increased…

Chronic pain: discovery in the brains of army veterans could pave way for personalised treatments

Study is first to investigate the neural hallmarks of co-occurring chronic pain and trauma in veterans, finding high, medium, and low symptom groups        Chronic pain and trauma often co-occur. However, most previous research investigated them in isolation and using subjective measures such as surveys, leading to an incomplete picture. A new study in Frontiers…

NICE recommends Sleepio app for insomnia

Sleepio is recommended as a cost saving option for treating insomnia and insomnia symptoms in primary care for people who would otherwise be offered sleep hygiene or sleeping pills. For people who may be at higher risk of other sleep disorder conditions, such as in pregnancy, or in people with comorbidities, a medical assessment should…

Positive CHMP opinion for Upstaza™ for the treatment of AADC deficiency

PTC Therapeutics, Inc. announced on May 20th that Upstaza™ (eladocagene exuparvovec; PTC-AADC) received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Once ratified by the European Commission, Upstaza will be the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency for patients…

A music based walking app for MS?

Biogen is looking to utilise a music-based digital therapeutic to help improve the gait of multiple sclerosis patients who may have difficulty walking. Developed by MedRhythms, the prescription app aims to do more than simply connect the beat of the music with walking cadence. The US-based company has been working on sensors and rehabilitation software…